
## Si-Ning Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5626868/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Low EVI1 expression at diagnosis predicted poor outcomes in pediatric Ph-negative B cell precursor acute lymphoblastic leukemia patients. Pediatric Hematology and Oncology, 2022, 39, 97-107.	0.8	1
2	Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation. Leukemia, 2022, 36, 267-270.	7.2	14
3	Donor activating killer cell immunoglobulinâ€like receptors genes correlated with Epstein–Barr virus reactivation after haploidentical haematopoietic stem cell transplantation. British Journal of Haematology, 2022, 196, 1007-1017.	2.5	4
4	Preemptive Interferon-α Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies. Frontiers in Immunology, 2022, 13, 757002.	4.8	13
5	Treatment outcome and efficacy of therapeutic plasma exchange for transplant-associated thrombotic microangiopathy in a large real-world cohort study. Bone Marrow Transplantation, 2022, , .	2.4	5
6	Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome. BMC Cancer, 2022, 22, 11.	2.6	2
7	Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft- <i>versus</i> -host disease after haploidentical allogeneic hematopoietic stem cell transplantation. Therapeutic Advances in Hematology, 2022, 13, 204062072110728.	2.5	8
8	Donor NKG2C homozygosity contributes to CMV clearance after haploidentical transplantation. JCI Insight, 2022, 7, .	5.0	8
9	Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantation. Cellular and Molecular Immunology, 2022, 19, 482-491.	10.5	15
10	Phase 1b/3 Pharmacokinetics and Safety Study of Intravenous Posaconazole in Adult Asian Participants at High Risk for Invasive Fungal Infections. Advances in Therapy, 2022, 39, 1697-1710.	2.9	1
11	Adoptive therapy with <scp>cytomegalovirus</scp> â€specific T cells for <scp>cytomegalovirus</scp> infection after haploidentical stem cell transplantation and factors affecting efficacy. American Journal of Hematology, 2022, 97, 762-769.	4.1	14
12	A Predicted Model for Refractory/Recurrent Cytomegalovirus Infection in Acute Leukemia Patients After Haploidentical Hematopoietic Stem Cell Transplantation. Frontiers in Cellular and Infection Microbiology, 2022, 12, 862526.	3.9	7
13	Functional Competence of NK Cells via the KIR/MHC Class I Interaction Correlates with DNAM-1 Expression. Journal of Immunology, 2022, 208, 492-500.	0.8	5
14	Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study. Therapeutic Advances in Hematology, 2022, 13, 204062072210952.	2.5	5
15	The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2022, 13, 814334.	4.8	3
16	Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial. BMC Medicine, 2022, 20, 140.	5.5	8
17	A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation. Experimental Hematology and Oncology, 2022, 11, 25.	5.0	19
18	Combination of <i>KIT</i> and <i>FLT3â€</i> ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission. Hematological Oncology, 2022, 40, 724-733.	1.7	2

#	Article	IF	CITATIONS
19	Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia. Bone Marrow Transplantation, 2022, 57, 1204-1206.	2.4	5
20	CMV infection combined with acute GVHD associated with poor CD8+ T-cell immune reconstitution and poor prognosis post-HLA-matched allo-HSCT. Clinical and Experimental Immunology, 2022, 208, 332-339.	2.6	6
21	An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study. Blood, 2022, 140, 516-520.	1.4	18
22	The impact of pretransplant serum ferritin on haploidentical hematopoietic stem cell transplant for acquired severe aplastic anemia in children and adolescents. Pediatric Blood and Cancer, 2022, 69, .	1.5	1
23	Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide. Annals of Hematology, 2021, 100, 169-180.	1.8	14
24	The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia. Clinical Transplantation, 2021, 35, e14160.	1.6	12
25	Haploidentical hematopoietic stem cell transplantation for patients with myeloid sarcoma: a single center retrospective study. Annals of Hematology, 2021, 100, 799-808.	1.8	2
26	Human herpesvirus 6 reactivation in unmanipulated haploidentical hematopoietic stem cell transplantation predicts the occurrence of grade II to IV acute graftâ€versusâ€host disease. Transplant Infectious Disease, 2021, 23, e13544.	1.7	5
27	Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center. Annals of Hematology, 2021, 100, 1203-1212.	1.8	10
28	Preâ€transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors. Cancer Communications, 2021, 41, 333-344.	9.2	5
29	Haploidentical Stem Cell Transplantation With a Novel Conditioning Regimen in Older Patients: A Prospective Single-Arm Phase 2 Study. Frontiers in Oncology, 2021, 11, 639502.	2.8	4
30	HCMV modulates câ€Mpl/IEXâ€1 pathwayâ€mediated megakaryo/thrombopoiesis via PDGFRα and αvβ3 recept after alloâ€HSCT. Journal of Cellular Physiology, 2021, 236, 6726-6741.	<sup>cors</sup> 4.1	1
31	Wilms' tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation. BMC Cancer, 2021, 21, 292.	2.6	5
32	A risk score system for stratifying the risk of relapse in B cell acute lymphocytic leukemia patients after allogenic stem cell transplantation. Chinese Medical Journal, 2021, 134, 1199-1208.	2.3	3
33	G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Acute Leukemia Patients in the First Complete Remission: A Registered Study. Frontiers in Oncology, 2021, 11, 631625.	2.8	8
34	Acute Cholecystitis Following Allogeneic Hematopoietic Stem Cell Transplantation: Clinical Features, Outcomes, Risk Factors, and Prediction Model. Transplantation and Cellular Therapy, 2021, 27, 253.e1-253.e9.	1.2	1
35	The Prognostic Significance of ZNF384 Fusions in Adult Ph-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: A Comprehensive Cohort Study From a Single Chinese Center. Frontiers in Oncology, 2021, 11, 632532.	2.8	9
36	Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2021, 100, 1267-1281.	1.8	3

#	Article	IF	CITATIONS
37	Risk factors and outcomes of diffuse alveolar haemorrhage after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 2097-2107.	2.4	9
38	Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy. Leukemia, 2021, 35, 3092-3100.	7.2	22
39	The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 67.	6.2	9
40	Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia. Current Medical Science, 2021, 41, 443-453.	1.8	3
41	Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor. Frontiers in Medicine, 2021, 8, 604085.	2.6	13
42	Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion. Frontiers of Medicine, 2021, 15, 728-739.	3.4	0
43	Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment. Annals of Hematology, 2021, 100, 2557-2566.	1.8	4
44	Interferon-α as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 2949-2956.	1.3	14
45	Risk Stratification of Cytogenetically Normal Acute Myeloid Leukemia With Biallelic CEBPA Mutations Based on a Multi-Gene Panel and Nomogram Model. Frontiers in Oncology, 2021, 11, 706935.	2.8	3
46	Hepatitis B Seropositive Status in Recipients or Donors Is Not Related to Worse Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 668.e1-668.e9.	1.2	3
47	Clinical risk factors and prognostic model for idiopathic inflammatory demyelinating diseases after haploidentical hematopoietic stem cell transplantation in patients with hematological malignancies. American Journal of Hematology, 2021, 96, 1407-1419.	4.1	5
48	Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-Versus-Host Disease. Frontiers in Immunology, 2021, 12, 749266.	4.8	12
49	A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy. Blood Advances, 2021, 5, 5479-5489.	5.2	6
50	Overt gastrointestinal bleeding following haploidentical haematopoietic stem cell transplantation: incidence, outcomes and predictive models. Bone Marrow Transplantation, 2021, 56, 1341-1351.	2.4	8
51	Allogeneic hematopoietic stem cell transplantation for intermediate-risk acute myeloid leukemia in the first remission: outcomes using haploidentical donors are similar to those using matched siblings. Annals of Hematology, 2021, 100, 555-562.	1.8	5
52	Machine-Learning Model for Resistance/Relapse Prediction in Immune Thrombocytopenia Using Gut Microbiota and Function Signatures. Blood, 2021, 138, 18-18.	1.4	1
53	Treatment Outcome and Efficacy of Therapeutic Plasma Exchange for Transplant-Associated Thrombotic Microangiopathy in a Real-World Large Cohort Study. Blood, 2021, 138, 1013-1013.	1.4	0
54	Detection of <i>CSRP2</i> Transcript Levels By Real-Time Quantitative PCR May be a Useful Tool for Monitoring Minimal Residual Disease in B-Cell ALL. Blood, 2021, 138, 3998-3998.	1.4	0

#	Article	IF	CITATIONS
55	Tacrolimus Plus High-Dose Dexamethasone Versus High-Dose Dexamethasone Alone As First-Line Treatment for Adult Immune Thrombocytopenia: The Phase 2, Open Label, Randomized Trial (TARGET) Tj ETQq1	1 01748431	4 æBT /Over
56	Chimeric Antigens Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission. Frontiers in Immunology, 2021, 12, 731435.	4.8	4
57	Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Oncology, 2021, 11, 773394.	2.8	8
58	First-line Therapy With Donor-derived Human Cytomegalovirus (HCMV)–specific T Cells Reduces Persistent HCMV Infection by Promoting Antiviral Immunity After Allogenic Stem Cell Transplantation. Clinical Infectious Diseases, 2020, 70, 1429-1437.	5.8	30
59	The Quantification of Minimal Residual Disease Pre―and Postâ€Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia. Cytometry Part B - Clinical Cytometry, 2020, 98, 75-87.	1.5	18
60	Influence of the degree of donor bone marrow hyperplasia on patient clinical outcomes after allogeneic hematopoietic stem cell transplantation. Science China Life Sciences, 2020, 63, 138-147.	4.9	4
61	Improved survival after offspring donor transplant compared with older agedâ€matched siblings for older leukaemia patients. British Journal of Haematology, 2020, 189, 153-161.	2.5	8
62	Autologous cord blood cell infusion in preterm neonates safely reduces respiratory support duration and potentially preterm complications. Stem Cells Translational Medicine, 2020, 9, 169-176.	3.3	16
63	Incidence, Risk Factors, Outcomes, and Risk Score Model of Acute Pancreatitis after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1171-1178.	2.0	8
64	Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as postâ€remission treatment for children with very highâ€risk philadelphia chromosome negative Bâ€cell acute lymphoblastic leukaemia in first complete remission. British Journal of Haematology, 2020, 188, 757-767.	2.5	17
65	Subgroup Analysis Can Optimize the Relapse-Prediction Cutoff Value for WT1 Expression After Allogeneic Hematologic Stem Cell Transplantation in Acute Myeloid Leukemia. Journal of Molecular Diagnostics, 2020, 22, 188-195.	2.8	4
66	Unmanipulated haploidentical hematopoietic stem cell transplantation for children with myelodysplastic syndrome. Pediatric Transplantation, 2020, 24, e13864.	1.0	5
67	Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Cytotherapy, 2020, 22, 755-761.	0.7	33
68	Preemptive interferon-α treatment could protect against relapse and improve long-term survival of ALL patients after allo-HSCT. Scientific Reports, 2020, 10, 20148.	3.3	7
69	Comparison of different cytomegalovirus diseases following haploidentical hematopoietic stem cell transplantation. Annals of Hematology, 2020, 99, 2659-2670.	1.8	13
70	<p>Both Methylation and Copy Number Variation Participated in the Varied Expression of PRAME in Multiple Myeloma</p> . OncoTargets and Therapy, 2020, Volume 13, 7545-7553.	2.0	2
71	Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1. Journal of Hematology and Oncology, 2020, 13, 52.	17.0	13
72	Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 2087-2097.	2.4	8

#	Article	IF	CITATIONS
73	Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplantation, 2020, 55, 2035-2042.	2.4	11
74	Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment. BMC Cancer, 2020, 20, 553.	2.6	21
75	Outcomes of symptomatic venous thromboembolism after haploidentical donor hematopoietic stem cell transplantation and comparison with human leukocyte antigen-identical sibling transplantation. Thrombosis Research, 2020, 194, 168-175.	1.7	2
76	Monosomal karyotype is associated with poor outcomes in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia receiving chemotherapy but not allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2020, 99, 1833-1843.	1.8	3
77	Detection of measurable residual disease may better predict outcomes than mutations based on nextâ€generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA. British Journal of Haematology, 2020, 190, 533-544.	2.5	14
78	Mutation topography and risk stratification for <i>de novo</i> acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 ( <i>NPM1</i> ) mutation or Fmsâ€like tyrosine kinase 3 internal tandem duplication ( <i>FLT3â€</i> ). British Journal of Haematology, 2020, 190, 274-283.	2.5	18
79	DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia. British Journal of Haematology, 2020, 190, 67-78.	2.5	11
80	Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia. Leukemia Research, 2020, 91, 106333.	0.8	11
81	Haploidentical stem cell transplantation in patients with chronic myelomonocytic leukemia. Science China Life Sciences, 2020, 63, 1261-1264.	4.9	8
82	Frequency, Risk Factors, and Outcome of Active Tuberculosis following Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1203-1209.	2.0	9
83	Incidence, risk factors, and outcomes of cytomegalovirus retinitis after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 1147-1160.	2.4	18
84	A retrospective analysis on anti-CD20 antibody–treated Epstein–Barr virus–related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation. Annals of Hematology, 2020, 99, 2649-2657.	1.8	2
85	Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection. Advances in Therapy, 2020, 37, 2493-2506.	2.9	5
86	Osteoclast stimulatory transmembrane protein ( OCâ€STAMP ) is a promising molecular prognostic indicator for multiple myeloma. European Journal of Haematology, 2020, 105, 185-195.	2.2	2
87	Prognostic factors and longâ€term followâ€up of basiliximab for steroidâ€refractory acute <scp>graftâ€versusâ€host disease</scp> : Updated experience from a largeâ€scale study. American Journal of Hematology, 2020, 95, 927-936.	4.1	32
88	Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study. Journal of Hematology and Oncology, 2020, 13, 27.	17.0	48
89	Different Effects of Pre-transplantation Measurable Residual Disease on Outcomes According to Transplant Modality in Patients With Philadelphia Chromosome Positive ALL. Frontiers in Oncology, 2020, 10, 320.	2.8	17
90	Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation. Frontiers in Immunology, 2020, 11, 620891.	4.8	21

#	Article	IF	CITATIONS
91	Comparison of central nervous system relapse outcomes following haploidentical vs identical-sibling transplant for acute lymphoblastic leukemia. Annals of Hematology, 2020, 99, 1643-1653.	1.8	3
92	Long-Term Follow-up of a Randomized Trial of Two Dose Levels of Antithymocyte Globulin in Haploidentical Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 20-20.	1.4	7
93	Mutations Based on Next-Generation Sequencing May be Complementally to Prognostic Risk in Myelodysplastic Syndromes. Blood, 2020, 136, 42-43.	1.4	0
94	PGE2 Dependent Inhibition of Macrophage Pyroptosis By MSCs Contributes to Alleviating aGVHD. Blood, 2020, 136, 15-15.	1.4	1
95	Development and Validation of a Prognostic Model for Transplant-Associated Thrombotic Microangiopathy Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 16-17.	1.4	0
96	Human Cytomegalovirus Selectively Suppresses the Megakaryo/Thrombopoiesis of PDGFR+ and αvβ3+ Megakaryocytes Via the TPO/c-Mpl Pathway after Allo-HSCT. Blood, 2020, 136, 25-25.	1.4	0
97	Risk and Prognostic Factors for Intracranial Hemorrhage in Elderly Patients with Immune Thrombocytopenia. Blood, 2020, 136, 14-15.	1.4	0
98	Comparison of efficacy between HLA6/6- and HLA3/6-matched haploidentical hematopoietic stem cell transplant in T-cell-replete transplants between parents and children. Science China Life Sciences, 2019, 62, 104-111.	4.9	6
99	High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia. Cancer Medicine, 2019, 8, 5459-5467.	2.8	7
100	Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients. Journal of Hematology and Oncology, 2019, 12, 88.	17.0	76
101	Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study. Journal of Hematology and Oncology, 2019, 12, 87.	17.0	24
102	The prognostic significance of Wilms' tumor gene 1 (WT1) expression at diagnosis in adults with Ph-negative B cell precursor acute lymphoblastic leukemia. Annals of Hematology, 2019, 98, 2551-2559.	1.8	8
103	Risk factors for chronic graft-versus-host disease after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation in acute myeloid leukemia. Frontiers of Medicine, 2019, 13, 667-679.	3.4	2
104	Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 1310-1318.	2.4	38
105	Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts. American Journal of Hematology, 2019, 94, 512-521.	4.1	51
106	Minimal residual disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Frontiers of Medicine, 2019, 13, 354-364.	3.4	8
107	FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients. Bone Marrow Transplantation, 2019, 54, 1462-1470.	2.4	9
108	MAGE genes: Prognostic indicators in AL amyloidosis patients. Journal of Cellular and Molecular Medicine, 2019, 23, 5672-5678.	3.6	6

#	Article	IF	CITATIONS
109	Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100Âdays after allogeneic stem cell transplantation. Annals of Hematology, 2019, 98, 1877-1883.	1.8	20
110	Incidence, risk factors and outcomes of sinusoidal obstruction syndrome after haploidentical allogeneic stem cell transplantation. Annals of Hematology, 2019, 98, 1733-1742.	1.8	6
111	Incidence, Risk Factors, and Outcome of Immune-Mediated Neuropathies (IMNs) following Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1629-1636.	2.0	6
112	Early myeloid-derived suppressor cells (HLA-DRâ^'/lowCD33+CD16â^') expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT. Journal of Hematology and Oncology, 2019, 12, 31.	17.0	35
113	Human Bone Marrow Mesenchymal Stem Cells Rescue Endothelial Cells Experiencing Chemotherapy Stress by Mitochondrial Transfer Via Tunneling Nanotubes. Stem Cells and Development, 2019, 28, 674-682.	2.1	48
114	<i>S100A16</i> suppresses the growth and survival of leukaemia cellsÂand correlates with relapse and relapse free survival in adults with Philadelphia chromosomeâ€negative Bâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2019, 185, 836-851.	2.5	7
115	Reduced β2-GPI is associated with increased platelet aggregation and activation in patients with prolonged isolated thrombocytopenia after allo-HSCT. Science China Life Sciences, 2019, 62, 921-929.	4.9	2
116	Positive stool culture could predict the clinical outcomes of haploidentical hematopoietic stem cell transplantation. Frontiers of Medicine, 2019, 13, 492-503.	3.4	5
117	Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies. Biology of Blood and Marrow Transplantation, 2019, 25, 1210-1217.	2.0	2
118	Dysregulated megakaryocyte distribution associated with nestin+ mesenchymal stem cells in immune thrombocytopenia. Blood Advances, 2019, 3, 1416-1428.	5.2	18
119	Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. Blood Advances, 2019, 3, 1303-1317.	5.2	43
120	Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation. Blood Advances, 2019, 3, 4312-4325.	5.2	27
121	Comparison analysis between haplo identical stem cell transplantation and matched sibling donor stem cell transplantation for high-risk acute myeloid leukemia in first complete remission. Science China Life Sciences, 2019, 62, 691-697.	4.9	16
122	A novel recombinant human thrombopoietin for treating prolonged isolated thrombocytopenia after allogeneic stem cell transplantation. Platelets, 2019, 30, 994-1000.	2.3	10
123	Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission. Clinical Cancer Research, 2019, 25, 1737-1748.	7.0	26
124	ADAM28 promotes tumor growth and dissemination of acute myeloid leukemia through IGFBP-3 degradation and IGF-I-induced cell proliferation. Cancer Letters, 2019, 442, 193-201.	7.2	12
125	Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era. Biology of Blood and Marrow Transplantation, 2019, 25, 1611-1620.	2.0	30
126	Chemotherapy plus DLI for relapse after haploidentical HSCT: the biological characteristics of relapse influences clinical outcomes of acute leukemia patients. Bone Marrow Transplantation, 2019, 54, 1198-1207.	2.4	12

#	Article	IF	CITATIONS
127	Occurrence and Severity of Donor Lymphocyte Infusion–Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 912-920.	2.0	4
128	Comments on the article: â€~Donorâ€derived <scp>CD</scp> 19â€targeted T cell infusion induces minimal residual diseaseâ€negative remission in relapsed Bâ€cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation'― Response to Pan <i>etÂal</i> . British Journal of Haematology, 2019, 184, 882-883.	2.5	0
129	Interferon-α salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation. Frontiers of Medicine, 2019, 13, 238-249.	3.4	18
130	ATRA Could Correct the Defective S1P-Mediated Cytoskeletal Reorganization in Proplatelet Formation of ITP. Blood, 2019, 134, 218-218.	1.4	1
131	Haploidentical Hematopoietic Stem Cell Transplantation May Improve Prognosis in Non-Infant Children with t(v;11q23)/MLL-Rearranged B-Acute Lymphoblastic Leukemia. Blood, 2019, 134, 2049-2049.	1.4	0
132	Integrated mRNA and miRNA profiling revealed deregulation of cellular stress response in bone marrow mesenchymal stem cells derived from patients with immune thrombocytopenia. Functional and Integrative Genomics, 2018, 18, 287-299.	3.5	15
133	Diminished expression of β2-GPI is associated with a reduced ability to mitigate complement activation in anti-GPIIb/IIIa-mediated immune thrombocytopenia. Annals of Hematology, 2018, 97, 641-654.	1.8	9
134	CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens. Annals of Hematology, 2018, 97, 485-495.	1.8	14
135	Acute kidney injury following haplo stem cell transplantation: incidence, risk factors and outcome. Bone Marrow Transplantation, 2018, 53, 483-486.	2.4	11
136	Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the <scp>TNFAIP</scp> 3/ <scp>NF</scp> â€₽B/ <scp>SMAD</scp> pathway in patients with immune thrombocytopenia. British Journal of Haematology, 2018, 180, 395-411.	2.5	32
137	Safety and efficacy of haploidentical stem cell transplantation for multiple myeloma. Bone Marrow Transplantation, 2018, 53, 507-510.	2.4	4
138	Impact of HLA allele mismatch at HLA-A, -B, -C, -DRB1, and -DQB1 on outcomes in haploidentical stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 600-608.	2.4	9
139	The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology. Journal of Hematology and Oncology, 2018, 11, 33.	17.0	233
140	lgG synthesis rate and anti-myelin oligodendrocyte glycoprotein antibody in CSF may be associated with the onset of CNS demyelination after haplo-HSCT. Annals of Hematology, 2018, 97, 1399-1406.	1.8	6
141	Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1936-1943.	2.0	25
142	T cell exhaustion characterized by compromised MHC class I and II restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. Clinical Immunology, 2018, 190, 32-40.	3.2	24
143	Combined prednisone and levothyroxine improve treatment of severe thrombocytopenia in hepatitis B with compensatory cirrhosis accompanied by subclinical and overt hypothyroidism. Science China Life Sciences, 2018, 61, 924-933.	4.9	1
144	Treatment of late-onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: the role of corticosteroids. Annals of Hematology, 2018, 97, 1209-1217.	1.8	10

#	Article	IF	CITATIONS
145	Monitoring of postâ€transplant <i><scp>CBFB</scp>â€<scp>MYH</scp>11</i> as minimal residual disease, rather than <i><scp>KIT</scp></i> mutations, can predict relapseÂafter allogeneic haematopoietic cell transplantation inAadults with inv(16) acute myeloid leukaemia. British Journal of Haematology, 2018, 180, 448-451.	2.5	26
146	Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 163-168.	2.0	6
147	Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 741-750.	2.0	36
148	Thrombotic microangiopathy with concomitant <scp>GI</scp> aGVHD after allogeneic hematopoietic stem cell transplantation: Risk factors and outcome. European Journal of Haematology, 2018, 100, 171-181.	2.2	13
149	Utility of flexible bronchoscopy with polymerase chain reaction in the diagnosis and management of pulmonary infiltrates in allogeneic <scp>HSCT</scp> patients. Clinical Transplantation, 2018, 32, e13146.	1.6	8
150	Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Chinese Medical Journal, 2018, 131, 2808-2816.	2.3	7
151	Relationship of Cell Compositions in Allografts with Outcomes after Haploidentical Transplantation for Acquired Severe Aplastic Anemia. Chinese Medical Journal, 2018, 131, 2185-2192.	2.3	5
152	Incidence, Risk Factors, Microbiology and Outcomes of Pre-engraftment Bloodstream Infection After Haploidentical Hematopoietic Stem Cell Transplantation and Comparison With HLA-identical Sibling Transplantation. Clinical Infectious Diseases, 2018, 67, S162-S173.	5.8	36
153	Interferon-α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study. Oncologist, 2018, 23, 1349-1357.	3.7	17
154	Safety of Autologous Cord Blood Cells for Preterms: A Descriptive Study. Stem Cells International, 2018, 2018, 1-9.	2.5	22
155	The role of collateral related donors in haploidentical hematopoietic stem cell transplantation. Science Bulletin, 2018, 63, 1376-1382.	9.0	27
156	Evaluation of HistoCheck as a Predictor of Clinical Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1866-1872.	2.0	1
157	Busulfan, Fludarabine, and Cyclophosphamide (BFC) conditioning allowed stable engraftment after haplo-identical allogeneic stem cell transplantation in children with adrenoleukodystrophy and mucopolysaccharidosis. Bone Marrow Transplantation, 2018, 53, 770-773.	2.4	18
158	Effectiveness and Tolerability of Micafungin in Chinese Patients with Invasive Fungal Infections: A Retrospective, Multicenter Study. Advances in Therapy, 2018, 35, 1400-1410.	2.9	3
159	Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21). Blood Cancer Journal, 2018, 8, 76.	6.2	21
160	Comparable Outcomes after Hematopoietic Stem Cell Transplantation from Mother Donors and Matched Unrelated Donors in Patients with Hematopoietic Malignancies. Blood, 2018, 132, 3463-3463.	1.4	0
161	Haplo-SCT Mediates Stronger GVL Effect Than HLA-Matched Sibling Allograft By Significantly Reducing Leukemia Burden. Blood, 2018, 132, 2186-2186.	1.4	0
162	First-Line Therapy with Donor Derived HCMV-Specific T Cells Reduce Persistent HCMV Infection after Allogenic Stem Cell Transplantation. Blood, 2018, 132, 727-727.	1.4	0

#	Article	IF	CITATIONS
163	Clonal Trajectories in Persons with Acute Myeloid Leukemia and Normal Cytogenetics Relapsing after Intensive Chemotherapy and after Allotransplants. Does Pretransplant Conditioning Contribute to Mutation Topography?. Blood, 2018, 132, 2813-2813.	1.4	0
164	Poor NKG2C+ Adaptive NK Cell Recovery at Early Stage after Allo-HSCT Increased the Occurrence of Refractory Cytomegalovirus Infection. Blood, 2018, 132, 360-360.	1.4	0
165	Association between C-reactive protein levels in the first 1–3 days post-transplant and allogeneic immune reactions. Biomarkers in Medicine, 2017, 11, 117-124.	1.4	1
166	The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. Journal of Hematology and Oncology, 2017, 10, 44.	17.0	51
167	Viral encephalitis after haploâ€identical hematopoietic stem cell transplantation: Causative viral spectrum, characteristics, and risk factors. European Journal of Haematology, 2017, 98, 450-458.	2.2	22
168	IFN-α Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Registry Study. Biology of Blood and Marrow Transplantation, 2017, 23, 1303-1310.	2.0	40
169	Recipientâ€donor KIR ligand matching prevents CMV reactivation postâ€haploidentical T cellâ€replete transplantation. British Journal of Haematology, 2017, 177, 766-781.	2.5	21
170	A Retrospective Study of Central Nervous System Invasive Fungal Disease after Allogeneic Stem Cell Transplantation: Risk Factors, Clinical Characteristics, and Outcomes. Biology of Blood and Marrow Transplantation, 2017, 23, 1158-1164.	2.0	8
171	Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2017, 96, 829-838.	1.8	39
172	Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Longâ€ŧerm outcomes of a prospective randomized trial. Cancer, 2017, 123, 2881-2892.	4.1	63
173	Donorâ€derived <scp>CD</scp> 19â€targeted T cell infusion induces minimal residual diseaseâ€negative remission in relapsed Bâ€cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. British Journal of Haematology, 2017, 179, 598-605.	2.5	87
174	Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes. Oncolmmunology, 2017, 6, e1356152.	4.6	28
175	Impaired Function of Bone Marrow Mesenchymal Stem Cells from Immune Thrombocytopenia Patients in Inducing Regulatory Dendritic Cell Differentiation Through the Notch-1/Jagged-1 Signaling Pathway. Stem Cells and Development, 2017, 26, 1648-1661.	2.1	36
176	Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. Lancet Haematology,the, 2017, 4, e487-e496.	4.6	38
177	Haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia in the imatinib era. Leukemia Research, 2017, 59, 136-141.	0.8	8
178	Higher dose of <scp>CD</scp> 34+ peripheral blood stem cells is associated with better survival after haploidentical stem cell transplantation in pediatric patients. Clinical Transplantation, 2017, 31, e12880.	1.6	4
179	Risk factors for herpes simplex virus-1/2 viremia and clinical outcomes following unmanipulated haploidentical haematopoietic stem cell transplantation. Journal of Clinical Virology, 2017, 95, 20-25.	3.1	10
180	Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. Journal of Hematology and Oncology, 2017, 10, 134.	17.0	132

#	Article	IF	CITATIONS
181	Adiponectin receptor agonist AdipoRon suppresses adipogenesis in C3H10T1/2 cells through the adenosine monophosphate-activated protein kinase signaling pathway. Molecular Medicine Reports, 2017, 16, 7163-7169.	2.4	15
182	Haploidentical Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2017, 23, 2143-2150.	2.0	19
183	Cysteine and glycine-rich protein 2 ( <i>CSRP2</i> ) transcript levels correlate with leukemia relapse and leukemia-free survival in adults with B-cell acute lymphoblastic leukemia and normal cytogenetics. Oncotarget, 2017, 8, 35984-36000.	1.8	23
184	Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget, 2017, 8, 41620-41630.	1.8	1
185	Impact of pre-transplant pulmonary infection developed in horizontal laminar flow unit on the outcome of subsequent allogeneic hematopoietic stem cell transplantation. Journal of Thoracic Disease, 2016, 8, 2219-2225.	1.4	2
186	Transplantation from haploidentical donor is not inferior to that from identical sibling donor for patients with chronic myeloid leukemia in blast crisis or chronic phase from blast crisis. Clinical Transplantation, 2016, 30, 994-1001.	1.6	11
187	Haploidentical hematopoietic stem cell transplantation for paediatric highâ€risk <scp>T</scp> â€cell acute lymphoblastic leukaemia. Pediatric Transplantation, 2016, 20, 572-580.	1.0	8
188	Salvage chemotherapy followed by granulocyte colonyâ€stimulating factorâ€primed donor leukocyte infusion with graftâ€vs.â€host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes. European Journal of Haematology, 2016, 96, 297-308.	2.2	37
189	High incidence of engraftment syndrome after haploidentical allogeneic stem cell transplantation. European Journal of Haematology, 2016, 96, 517-526.	2.2	8
190	Atorvastatin enhances endothelial cell function in posttransplant poor graft function. Blood, 2016, 128, 2988-2999.	1.4	73
191	Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 1080-1086.	2.0	16
192	High-dose corticosteroid associated with catheter-related thrombosis after allogeneic hematopoietic stem cell transplantation. Thrombosis Research, 2016, 144, 6-11.	1.7	5
193	Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study. Clinical Cancer Research, 2016, 22, 3467-3476.	7.0	142
194	Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation. Journal of Clinical Oncology, 2016, 34, 1855-1863.	1.6	100
195	Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation in First Complete Remission Can Abrogate the Poor Outcomes of Children with Acute Myeloid Leukemia Resistant to the First Course of Induction Chemotherapy. Biology of Blood and Marrow Transplantation, 2016, 22, 2235-2242.	2.0	11
196	Platelet-Derived Growth Factor-BB Protects Mesenchymal Stem Cells (MSCs) Derived From Immune Thrombocytopenia Patients Against Apoptosis and Senescence and Maintains MSC-Mediated Immunosuppression. Stem Cells Translational Medicine, 2016, 5, 1631-1643.	3.3	57
197	Clinical characteristics and risk factors of Intracranial hemorrhage in patients following allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2016, 95, 1637-1643.	1.8	27
198	Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study. Oncolmmunology, 2016, 5, e1250992.	4.6	21

#	Article	IF	CITATIONS
199	Minimal residual disease- and graft-vshost disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant. Journal of Hematology and Oncology, 2016, 9, 87.	17.0	57
200	Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation. Journal of Infection, 2016, 73, 261-270.	3.3	19
201	Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with highâ€risk acute lymphoblastic leukemia. International Journal of Cancer, 2016, 139, 2106-2115.	5.1	47
202	Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation. Chinese Journal of Cancer, 2016, 35, 46.	4.9	11
203	Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2016, 95, 1233-1240.	1.8	16
204	Allogeneic hematopoietic cell transplantation for adult patients with treatment-related acute myeloid leukemia during first remission: Comparable to de novo acute myeloid leukemia. Leukemia Research, 2016, 47, 8-15.	0.8	7
205	Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia. BMC Cancer, 2016, 16, 269.	2.6	31
206	Characterization of thrombopoietin kinetics within 60 days after allogeneic hematopoietic stem cell transplantation and its correlation with megakaryocyte ploidy distribution. Clinical Transplantation, 2016, 30, 170-178.	1.6	11
207	Increased prostacyclin levels inhibit the aggregation and activation of platelets via the PI3K–AKT pathway in prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Thrombosis Research, 2016, 139, 1-9.	1.7	8
208	Combined model of the EBMT score modified model and the HCT-CI improves the stratification of high-risk patients undergoing unmanipulated haploidentical blood and marrow transplantation. Leukemia and Lymphoma, 2016, 57, 2133-2139.	1.3	8
209	Risk factors for cytomegalovirus DNAemia following haploidentical stem cell transplantation and its association with host hepatitis B virus serostatus. Journal of Clinical Virology, 2016, 75, 10-15.	3.1	21
210	<i>Helicobacter pylori</i> infection influences the severity of thrombocytopenia and its treatment response in chronic hepatitis B patients with compensatory cirrhosis: A multicenter, observational study. Platelets, 2016, 27, 223-229.	2.3	7
211	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: To Allogeneic Stem Cell Transplantation or Not? a Single Center Experience. Blood, 2016, 128, 2308-2308.	1.4	1
212	Rosiglitazone Promotes Bone Marrow Adipogenesis to Impair Myelopoiesis under Stress. PLoS ONE, 2016, 11, e0149543.	2.5	19
213	Increased reactive oxygen species and exhaustion of quiescent CD34-positive bone marrow cells may contribute to poor graft function after allotransplants. Oncotarget, 2016, 7, 30892-30906.	1.8	48
214	Haploidentical Stem Cell Transplantation for Rare Pediatric Diseases at Peking University People's Hospital. Blood, 2016, 128, 5848-5848.	1.4	0
215	Polymorphisms of CTLA-4 Are Associated with Treatment Outcome in Multiple Myeloma Patients Receiving Bortezomib-Based Regimens. Blood, 2016, 128, 3323-3323.	1.4	0
216	ADAM28 Enhanced the Growth and Dissemination of AML and Identified a Subgroup of AML Patients with a High Risk of Relapse in a Prospective Clinical Study. Blood, 2016, 128, 2902-2902.	1.4	0

#	Article	IF	CITATIONS
217	Optimal Dose of Antithymocyte Globulin in Conditioning Regimens for Unmanipulated Haploidentical Haematopoietic Stem Cell Transplantation: Long-Term Outcomes of a Prospective Randomised Trial. Blood, 2016, 128, 3433-3433.	1.4	1
218	Association Between C-Reactive Protein in the First 1-3 Days Post-Transplant and Allogeneic Immune Reactions in Pediatric Haploidentical Stem Cell Transplantation. Blood, 2016, 128, 5794-5794.	1.4	0
219	Haploidentical stem cell transplantation in patients aged 50Âyr and older with leukemia: similar outcomes compared to younger adults. Clinical Transplantation, 2015, 29, 523-530.	1.6	14
220	Infusionâ€related febrile reaction after haploidentical stem cell transplantation in children is associated with higher rates of engraftment syndrome and acute graftâ€versusâ€host disease. Pediatric Transplantation, 2015, 19, 918-924.	1.0	11
221	Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT. Journal of Hematology and Oncology, 2015, 8, 116.	17.0	34
222	Recipient expression of ligands for donor inhibitory KIRs enhances NKâ€cell function to control leukemic relapse after haploidentical transplantation. European Journal of Immunology, 2015, 45, 2396-2408.	2.9	42
223	Lowâ€dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical <scp>HSCT</scp> . Clinical Transplantation, 2015, 29, 594-605.	1.6	16
224	Febrile reaction associated with the infusion of haploidentical peripheral blood stem cells: incidence, clinical features, and risk factors. Transfusion, 2015, 55, 2023-2031.	1.6	16
225	The impact of donor characteristics on the immune cell composition of mixture allografts of granulocyte–colonyâ€stimulating factor–mobilized marrow harvests and peripheral blood harvests. Transfusion, 2015, 55, 2874-2881.	1.6	18
226	Mitochondrial Reactive Oxygen Species Regulate Adipocyte Differentiation of Mesenchymal Stem Cells in Hematopoietic Stress Induced by Arabinosylcytosine. PLoS ONE, 2015, 10, e0120629.	2.5	67
227	Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood, 2015, 125, 3956-3962.	1.4	387
228	Haploidentical Hematopoietic Stem Cell Transplantation without InÂVitro T Cell Depletion for the Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1110-1116.	2.0	44
229	Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy. Leukemia and Lymphoma, 2015, 56, 3116-3123.	1.3	31
230	Epstein-Barr Virus–Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes. Biology of Blood and Marrow Transplantation, 2015, 21, 2185-2191.	2.0	46
231	Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. Journal of Hematology and Oncology, 2015, 8, 84.	17.0	160
232	Haploidentical hematopoietic stem cell transplantation in adults with Philadelphiaâ€negative acute lymphoblastic leukemia: No difference in the high―and lowâ€risk groups. International Journal of Cancer, 2015, 136, 1697-1707.	5.1	42
233	Long-Term Treatment with Rosiglitazone Delays Hematopoietic Recovery in Response to Stress. Blood, 2015, 126, 4769-4769.	1.4	0
234	Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 929-936.	2.0	28

#	Article	IF	CITATIONS
235	Total Body Irradiation and Cyclophosphamide Plus Antithymocyte Globulin Regimen Is Well Tolerated and Promotes Stable Engraftment as a Preparative Regimen before T Cell–Replete Haploidentical Transplantation for Acute Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 1176-1182.	2.0	21
236	The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma. Molecular Cancer, 2014, 13, 25.	19.2	10
237	Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used as Post-Remission Therapy in Adults with Standard-Risk Acute Lymphoblastic Leukemia in First Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 1314-1321.	2.0	36
238	Who is the best donor for a related HLA haplotype-mismatched transplant?. Blood, 2014, 124, 843-850.	1.4	285
239	Comparative Survival of Haploidentical and Matched Related Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. Blood, 2014, 124, 2591-2591.	1.4	0
240	Risk-Stratification Directed Prophylaxis with Additional Low-Dose of Methylprednisolone Can Reduce Acute Graft-Versus-Host Disease for Patients with Hematological Malignancies after Allogeneic SCT: A Randomized, Controlled, Clinical Trial. Blood, 2014, 124, 40-40.	1.4	0
241	Immunosuppression for 6-8 weeks after modified donor lymphocyte infusion reduced acute graft-versus-host disease without influencing graft-versus-leukemia effect in haploidentical transplant. Chinese Medical Journal, 2014, 127, 3602-9.	2.3	16
242	Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity. Annals of Hematology, 2013, 92, 1111-1119.	1.8	87
243	Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without <i>in vitro </i>	2.2	55
244	MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood, 2013, 121, 4056-4062.	1.4	277
245	Intracranial Hemorrhage and Mortality In 1461 Patients After Allogeneic Hematopoietic Stem Cell Transplantation For 6-Year Follow-Up: Study Of 44 Cases. Blood, 2013, 122, 3322-3322.	1.4	12
246	Risk stratification–directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood, 2012, 119, 3256-3262.	1.4	264
247	The effect of HLA disparity on clinical outcome after HLAâ€haploidentical blood and marrow transplantation. Clinical Transplantation, 2012, 26, 284-291.	1.6	39
248	A Clinical Study On Rituximab for Probable and Proven EBV Disease Post Haematopoietic Stem-Cell Transplantation. Blood, 2012, 120, 4512-4512.	1.4	0
249	Superior Graft-versus-Leukemia Effect Associated with Transplantation of Haploidentical Compared with HLA-Identical Sibling Donor Grafts for High-Risk Acute Leukemia: An Historic Comparison. Biology of Blood and Marrow Transplantation, 2011, 17, 821-830.	2.0	149
250	Coinfusion of Mesenchymal Stromal Cells Facilitates Platelet Recovery Without Increasing Leukemia Recurrence in Haploidentical Hematopoietic Stem Cell Transplantation: A Randomized, Controlled Clinical Study. Stem Cells and Development, 2011, 20, 1679-1685.	2.1	64
251	Stromal-derived factor-1 deficiency in the bone marrow of acute myeloid leukemia. International Journal of Hematology, 2011, 93, 750-759.	1.6	6
252	Superiority of Haploidentical Related Hematopoietic Stem-Cell Transplantation Over Chemotherapy Alone for Patients with Intermediate- or Poor- Risk Acute Myeloid Leukemia in First Complete Remission,. Blood, 2011, 118, 4161-4161.	1.4	0

#	Article	IF	CITATIONS
253	Leukemia Initiating Cells: New Markers for Minimal Residual Disease Monitoring in B-Precursor Acute Lymphoblastic Leukemia. Blood, 2011, 118, 2528-2528.	1.4	0
254	Pre-Emptive Therapy with Modified Donor Lymphocyte Infusion Could Reduce Relapse and Improve Survival in Standard-Risk Acute Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2011, 118, 659-659.	1.4	0
255	CD4 + CD25 - CD69 + t Cells Is a Novel Subset of Regulatory T Cells Involved In the Prevention of Acute Graft-Versus-Host Disease In Human. Blood, 2010, 116, 1250-1250.	1.4	1
256	Imatinib Mesylate Versus Allogeneic HSCT for Patients with Chronic Myelogenous Leukemia In Accelerated Phase: A Single Center Experience In China After a 9-Year Follow-up. Blood, 2010, 116, 2347-2347.	1.4	0
257	Comparable Immune Reconstitution Achieved Following Unmanipulated HLA-Mismatched/Haploidentical Transplantation and HLA-Identical Sibling Transplantation. Blood, 2010, 116, 2312-2312.	1.4	0
258	Prolonged Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation: Association with Reduced Ploidy and Immaturation of Megakaryocytes. Blood, 2010, 116, 4695-4695.	1.4	0
259	IL-17-Producing T Cells Contribute to Mediate Acutegraft-Versus-Disease In Patients Undergoing Unmanipulated Blood and MarrowTransplantation. Blood, 2010, 116, 2310-2310.	1.4	0
260	Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial. Chinese Medical Journal, 2010, 123, 2199-205.	2.3	3
261	Treatment of Acute Leukemia with Unmanipulated HLA-Mismatched/Haploidentical Blood and Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 257-265.	2.0	278
262	Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica, 2007, 92, 414-417.	3.5	147
263	Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood, 2006, 107, 3065-3073.	1.4	482
264	HLA Mismatched/Haploidentical Haematopoietic Stem Cell Transplantation for the Treatment of Chronic Myelogenous Leukemia Blood, 2006, 108, 3154-3154.	1.4	0
265	Subclinical Alterations in Coagulation in Patients during Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation Blood, 2005, 106, 5292-5292.	1.4	0
266	Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment. Frontiers in Immunology, 0, 13, .	4.8	3